Journal of Clinical Medicine

Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies

By María Marques Vidas, Borja Quiroga, José María Portolés, María Auxiliadora Bajo

Abstract

Obesity-related chronic kidney disease (ob-CKD) is an increasingly prevalent condition whose pathogenesis extends beyond excess body mass to the metabolic dysfunction of visceral adipose tissue (VAT).

The paper

María Marques Vidas, Borja Quiroga, José María Portolés, María Auxiliadora Bajo

Instituto de Salud Carlos III

Journal of Clinical Medicine, 16 Sep 2026, CC BY

doi.org/10.3390/jcm15187201 PubMed 42795973

Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial

Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies

Abstract

The paper

More on GLP-1 receptor agonists

Semaglutide may protect kidneys by reducing vascular resistance

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

A triple-target drug cut body weight by up to 19.7% in a trial